CaroGen

company

About

CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.40M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
1 - 10
Operating Status
Active

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology developed by Professor John Rose at Yale University School of Medicine. We are dedicated to creating recombinant and replication proficient-virus like vesicle (VLV)-based vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1.40M
CaroGen has raised a total of $1.40M in funding over 2 rounds. Their latest funding was raised on Mar 27, 2019 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 27, 2019 Grant $1.40M 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
1
1
CaroGen is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant